Cigna Group stock trades steady as earnings growth and buybacks support valuation

Cigna Group stock reflects a mix of health services growth and capital returns, with 2024 guidance implying rising earnings and sizable share repurchases that frame the current valuation for investors.

Cigna Group stock mirrors a business that is leaning on health services growth and aggressive capital returns to shape its 2024 profile. According to the companys full year 2023 results published on 2 February 2024, Cigna Group reported adjusted income from operations of $7.3 billion for 2023, up from $6.7 billion in 2022, showing earnings growth backed by its health services and insurance operations, as outlined on the companys investor relations site covering the 2023 results and 2024 outlook. The same release shows that Cigna Group is listed on the New York Stock Exchange, anchoring its presence in the US large cap health care universe for investors who follow the S&P 500 health insurance and services segment.

Adjusted income from operations reaches $7.3 billion

In its 2023 reporting, Cigna Group highlighted that consolidated adjusted income from operations climbed to $7.3 billion for the full year 2023 compared with $6.7 billion in 2022, representing an increase of roughly 9% year on year, as disclosed in the 2023 results release on 2 February 2024 summarizing the earnings trajectory. Management also reported that adjusted income from operations per share for 2023 was $25.15, up from $23.27 in 2022, which reflects the impact of both earnings growth and the effect of share repurchases on per share metrics over the period. The company noted in the same document that total revenues reached approximately $195 billion for 2023, compared with around $181 billion in 2022, illustrating revenue expansion of about $14 billion that underpins its health services and insurance franchises.

For 2024, Cigna Group is guiding toward further earnings expansion. In its 2024 outlook in the February 2024 release, the company projected adjusted income from operations of at least $8.0 billion for full year 2024, signaling a planned increase from the $7.3 billion achieved in 2023 according to the same investor relations communication setting out the 2024 guidance. The company simultaneously targeted adjusted earnings per share of at least $28.25 for 2024, compared with the $25.15 delivered in 2023, indicating that management is planning for per share earnings to grow by more than $3 over the course of the year if business trends and capital allocation plans remain on track.

Capital returns and share repurchases shape EPS outlook

Cigna Group has also emphasized capital returns as a central element of its equity story. According to the 2023 results and 2024 outlook release dated 2 February 2024, Cigna Group returned a total of $8.4 billion to shareholders in 2023 through a combination of share repurchases and dividends, including $7.2 billion of share repurchases, highlighting its willingness to use free cash flow and balance sheet capacity for buybacks detailing shareholder distributions. The same document noted that in 2023 the company paid $1.2 billion in dividends, which complements the buyback program and provides a cash income component alongside potential capital appreciation for shareholders.

The 2024 outlook from the company envisions capital deployment continuing at a significant scale. As stated in the February 2024 investor communication, management expects to deploy at least $10 billion of capital in 2024 primarily through share repurchases, driven by strong cash generation from operations and an investment grade balance sheet, according to the guidance language in the 2023 results release describing expected 2024 capital deployment. In practical terms, sizable share repurchases can reduce the share count over time, which in turn can support growth in adjusted earnings per share even in a more moderate revenue growth environment, something long term investors often consider when assessing total return prospects.

These capital return figures also feed into the companys leverage and cash flow considerations. According to commentary in the 2023 results and 2024 outlook release, Cigna Group generated strong operating cash flow in 2023, providing the resources to fund both investment needs in its Evernorth Health Services and Cigna Healthcare segments and capital returns to owners. While the exact 2023 cash flow from operations figure in dollars was detailed in the full financial statements, managements focus in the summarized release is on the sustainability of cash generation relative to the commitment to at least $10 billion of capital deployment in 2024. For investors, the interaction between cash flow, share repurchases and dividend growth is central to understanding how Cigna Group stock may behave relative to peers in the health insurance and pharmacy benefit management space over a multi year horizon.

Evernorth Health Services drives revenue scale

Cigna Group organizes its operations mainly through two segments, Evernorth Health Services and Cigna Healthcare, and the earnings and revenue contributions of these segments help frame the drivers behind Cigna Group stock. According to the companys 2023 results materials, Evernorth Health Services generated a substantial portion of the consolidated revenue base, contributing well over half of total consolidated revenues in 2023, as detailed in the segment overview accompanying the 2 February 2024 release on the investor relations site summarizing segment performance. This segment houses pharmacy benefit management and other health services solutions that serve employers, health plans, and government clients.

Within Cigna Healthcare, which provides medical and related benefits, the company underscored membership trends and disciplined pricing as factors supporting profitability and growth. The 2023 results discussion highlighted medical customer relationships in the tens of millions, reflecting the scale of the business, though the detailed customer count table is contained in the full year statistical supplement associated with the press release. From an investor perspective, the combination of a large health services platform through Evernorth and a significant medical insurance franchise through Cigna Healthcare contributes to the stability of cash flows that underpin the previously mentioned 2023 adjusted income from operations of $7.3 billion and the 2024 outlook for at least $8.0 billion of adjusted income from operations.

Cigna Healthcare solutions and customer reach

The Cigna Healthcare segment focuses on commercial, government, and international markets, providing medical, dental, and related products. According to management commentary in the 2 February 2024 release summarizing 2023 results and 2024 expectations, Cigna Healthcare continued to emphasize customer retention and value based arrangements, which contributed to the year on year growth in adjusted income from operations from $6.7 billion in 2022 to $7.3 billion in 2023. These operational advances, combined with the contribution from Evernorth Health Services, support the companys confidence in targeting at least $28.25 of adjusted earnings per share for 2024, as stated in the same outlook document. For investors assessing Cigna Group stock, the interplay between segment performance, customer metrics, and capital deployment strategies features prominently in fundamental analysis.

Recent trading context for Cigna Group stock

While real time share prices change continuously during trading sessions on the New York Stock Exchange, financial data providers have recently highlighted Cigna Group as a large capitalization health care company with a market value measured in tens of billions of dollars, based on share prices observed in 2024 in combination with an outstanding share count aligned with the capital return and repurchase data reported in the companys 2023 results. The alignment between market capitalization and the adjusted income from operations of $7.3 billion in 2023, together with guidance for at least $8.0 billion of adjusted income from operations in 2024, allows investors to compare valuation multiples such as price to earnings and enterprise value to earnings across the health insurance and services peer group.

For long term holders, the fact that Cigna Group returned $8.4 billion to shareholders in 2023, including $7.2 billion in share repurchases and $1.2 billion in dividends, sets a reference point for evaluating the sustainability of capital returns relative to the companys earnings and cash flow base. Looking ahead, the companys expectation to deploy at least $10 billion of capital in 2024, largely via buybacks as per its 2024 outlook, provides an additional framework for understanding potential per share earnings accretion, assuming that operating trends remain consistent with the guidance. Cigna Group stock therefore reflects a balance between growth in health services and insurance operations, ongoing capital deployment, and the broader valuation environment for US managed care and pharmacy benefit companies.

Cigna Group key data

• Company: The Cigna Group Inc.
• ISIN: US1255231003
• Ticker: NYSE: CI
• Trading venue: NYSE
• Sector / Industry: Health Care / Managed Health Care and Health Services
• Index membership: S&P 500